Abstract
Background
People with human immunodeficiency virus (PWH) with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East Africa, but studies are lacking. Leishmania parasitemia has been used as proxy for infectiousness.
Methods
This study is nested within the Predicting Visceral Leishmaniasis in HIV-InfectedPatients (PreLeisH) prospective cohort study, following 490 PWH free of VL at enrollment for up to 24–37 months in northwest Ethiopia. Blood Leishmania polymerase chain reaction (PCR) was done systematically. This case series reports on 10 PWH with chronic VL (≥3 VL episodes during follow-up) for up to 37 months, and 3 individuals with asymptomatic Leishmania infection for up to 24 months.
Results
All 10 chronic VL cases were male, on antiretroviral treatment, with 0–11 relapses before enrollment. Median baseline CD4 count was 82 cells/µL. They displayed 3–6 VL treatment episodes over a period up to 37 months. Leishmania blood PCR levels were strongly positive for almost the entire follow-up (median cycle threshold value, 26 [interquartile range, 23–30]), including during periods between VL treatment. Additionally, we describe 3 PWH with asymptomatic Leishmania infection and without VL history, with equally strong Leishmania parasitemia over a period of up to 24 months without developing VL. All were on antiretroviral treatment at enrollment, with baseline CD4 counts ranging from 78 to 350 cells/µL.
Conclusions
These are the first data on chronic parasitemia in PWH from Leishmania donovani–endemic areas. PWH with asymptomatic and symptomatic Leishmania infection could potentially be highly infectious and constitute Leishmania superspreaders. Xenodiagnosis studies are required to confirm infectiousness.
Keywords: visceral leishmaniasis, Africa, PCR, transmission, superspreader
People with HIV in northwest Ethiopia with asymptomatic and symptomatic Leishmania infection displayed chronic high-level parasitemia for up to 37 months. These individuals could be highly infectious and constitute Leishmania superspreaders. Xenodiagnosis studies are required to confirm infectiousness.
Visceral leishmaniasis (VL) is a neglected tropical disease transmitted by the bites of sandflies. In East Africa and the Indian subcontinent, VL is caused by parasites belonging to the Leishmania donovani species, with anthroponotic transmission [1, 2]. In the Mediterranean region and Latin America, VL is caused by Leishmania infantum and transmission is predominantly zoonotic. Manifestations of VL include persistent fever, splenomegaly, and pancytopenia. Without treatment, VL is usually fatal [1]. According to the World Health Organization (WHO), around 30 000 cases are estimated to occur annually at the global level [3]. East Africa currently has the highest VL burden globally.
The ambition of VL elimination in East Africa has recently been stated by WHO [4]. To inform an elimination strategy, a good understanding of which individuals are most likely to transmit the disease is essential. For most infectious diseases, infectiousness is largely driven by small subgroups, sometimes referred to as superspreaders [5, 6]. People with human immunodeficiency virus (PWH) have been put forward as potentially important sources of infection [7, 8].
Even while on antiretroviral treatment (ART), PWH generally show a decreased parasitological response to VL treatment, with a subgroup of patients manifesting with repeated VL relapses [9, 10]. Thus, there are concerns that such patients could remain infectious for many years. Whether PWH can be infectious without displaying clinical VL manifestations (ie, individuals with asymptomatic Leishmania infection [ALI]) is not well characterized for L. donovani–endemic areas. However, this could have huge implications, as such individuals would not seek VL care and could constitute hidden reservoirs of VL transmission.
In France, a chronic form of VL was described in 2010 in a case series of 10 PWH with multiple VL relapses followed up for up to 13 years [11]. Polymerase chain reaction (PCR) and blood culture results indicated continuous parasite circulation despite treatment and secondary prophylaxis, both during asymptomatic periods and the recurrent symptomatic VL episodes. This condition was labeled as active chronic VL—chronic due to the multiple VL episodes over many years, and active due to the continuous blood parasite circulation. In France, VL is caused by L. infantum; human immunodeficiency virus (HIV) coinfection rates are low; and, like in all L. infantum–endemic areas, humans are generally only considered to play a minor role in transmission. In contrast, East Africa is marked by high rates of HIV coinfection, with around 20% of people with VL coinfected with HIV in some parts of Ethiopia [9], and transmission is anthroponotic. Whether chronic parasitemia or active chronic VL also occurs in L. donovani–endemic areas, where it could have far-reaching implications, is not known.
In the Predicting Visceral Leishmaniasis in HIV-Infected Patients (PreLeisH) study, 490 PWH were followed up for up to 2 years in a VL-endemic area in northwest Ethiopia, with the aim to identify early predictors of VL [12]. This study also provided a unique opportunity to monitor parasite circulation in PWH over time. In this case series, we report on 10 PWH with chronic VL, defined as those developing at least 3 VL episodes during follow-up. They represent 29% of all those developing VL in the PreLeisH study. Additionally, we report on 3 HIV-coinfected individuals with ALI. Both chronic VL and ALI cases displayed high levels of parasites in their peripheral blood for up to 37 months. These are the first data ever reported on chronic parasitemia in PWH from L. donovani–endemic areas, providing important information for VL elimination efforts.
METHODS
Study Design, Set-up, and Population
This is a case series nested within the PreLeisH prospective cohort study [12], conducted between October 2017 and May 2021 in Abdurafi health center in the Amhara region, northwest Ethiopia. In the PreLeisH study, 490 PWH free of VL at the time of enrollment were followed up for up to 24 months. This included individuals with or without previous VL episodes. Individuals developing VL during the study period (incident VL cases) were followed up until the end of the study.
In this case series, we included all participants from the PreLeisH study who developed at least 3 VL episodes (defined as chronic VL) during follow-up in the study, to identify individuals most likely to be potentially infectious for a prolonged period. The 9 cases with 2 VL episodes during the study were hence not included in this case series. In addition, we included all 3 participants with ALI who displayed high parasitemia throughout the follow-up period, despite not having any VL episode before or during the study.
Study Procedures
A study visit was planned each time the study participants presented for their routine HIV consultation (usually every 3–6 months) and in between these scheduled visits if patients presented with symptoms compatible with VL. In addition to a full clinical evaluation, blood and urine samples were collected. For the first VL episode, Leishmania tests were also collected weekly until the end of treatment. After each VL episode, follow-up visits were scheduled at 6 and 12 months.
Study participants were evaluated for VL at each study visit and, in case of clinical suspicion (fever >2 weeks with weight loss and/or splenomegaly), referred for routine diagnostic workup. VL diagnosis was based on microscopic examination of spleen or bone marrow aspirates [13], and grading of the parasite load was done as reported before [14]. Treatment of VL relied on liposomal amphotericin B (AmBisome) infusions and oral miltefosine combination therapy for 28 days, or longer if indicated [15]. A VL treatment episode was defined as any follow-up visit at which VL treatment was started based on the routine VL diagnostic workup. Study-specific Leishmania tests such as Leishmania PCR, urine antigen, and serology results besides the rK39 rapid diagnostic test (RDT) were not available to the physician at the time of the clinical visit. At the end of treatment, a parasitological test of cure was done by microscopy on tissue aspirates.
Laboratory Assays and Quality Control
Leishmania tests were done at each study visit. This entailed Leishmania serological tests including the direct agglutination test (DAT; Institute of Tropical Medicine, Antwerp, Belgium), rK39 RDT (IT LEISH, Bio-Rad, Hercules, California), and rK39 enzyme-linked immunosorbent assay (ELISA) (Serion Leishmania IgG ELISA, Serion Diagnostics, Würzburg, Germany). Tests were executed as reported before [16]. The rK39 RDT was reported as positive or negative. For the rK39 ELISA test, results were interpreted as follows: values <10 U/mL were negative, 10–15 U/mL were borderline positive, and ≥15 U/mL were positive. A DAT titer ≥1/1600 was used to define positive tests, in line with previous studies [16].
In addition, 2 parasitological tests were done: real-time PCR targeting kinetoplast DNA (kDNA) on whole blood and a Leishmania urine antigen test (KAtex, Kalon Biological Ltd, Guilford, United Kingdom). The KAtex test is a semi-quantitative urine assay, with 3 levels of agglutination: 1+: weakly positive; 2+: moderately positive; 3+: strongly positive. Detection of Leishmania kDNA by quantitative PCR (qPCR) was done as described before [17, 18]. DNA was isolated from 300 μL whole blood using the Maxwell 16 LEV Blood DNA purification extraction kit (Promega, Leiden, The Netherlands) with the automated Maxwell 16 Instrument (AS1000, Promega). The reaction was run on a Rotor-Gene Q instrument (Qiagen, Venlo, The Netherlands). Results were expressed in cycle threshold (Ct) values. CD4 counts were done using the BD FACSCount (Becton Dickinson), typically every 6 months. The full blood count, CD4 count, and the rK39 RDT were performed locally at Abdurafi health center. Samples for DAT, rK39 ELISA, KAtex, and PCR were transported in cold chain boxes to the Leishmaniasis Training and Research Center in Gondar, Ethiopia for storage and further analysis in batch. In line with previous publications [16, 18, 19], ALI was defined as at least 1 of the Leishmania tests being positive in an individual without symptoms/signs of VL such as persisting fever with weight loss and splenomegaly.
Data Collection and Quality Control
The PreLeisH study was conducted in a clinical research network that has been conducting VL clinical research in Ethiopia for over a decade, with support from the Clinical Trials Unit and the Clinical Reference Laboratory of the Institute of Tropical Medicine, Antwerp, Belgium. Study-related information was collected using a clinical and a laboratory paper case report form and subsequently transcribed into electronic case report forms, using the Macro data capture system. Data quality was monitored throughout the study, including on-site monitoring visits by the Clinical Trials Unit.
Statistical Analysis
Only descriptive analysis was done. Continuous variables were summarized using median and interquartile range (IQR). Categorical variables were summarized using frequencies and proportions. Statistical analysis was done using Stata version 15 software (StataCorp, College Station, Texas).
Ethical Considerations
The study was approved by the institutional/ethics review board of the Institute of Tropical Medicine, the University of Antwerp, the University of Gondar, the Amhara Regional Health Bureau, Médecins sans Frontières, and the Ethiopian research ethics review committee.
RESULTS
Characteristics of Study Participants
Among the 490 PWH followed up in the PreLeisH study, 34 developed VL during the study. Of these, 19 (56%) had multiple VL episodes during follow-up and 10 (29%) had 3 or more VL episodes over a period of up to 37 months. These 10 cases were included in this article and are referred to as chronic VL cases.
All participants were male, with a median age of 30 years (IQR, 28–37 years). Three were residing in the (VL-endemic) study area only temporary, 3 were stable residents having lived in the area since birth, and 4 were stable residents but born outside of the study area. One participant was a farmer, and all others were daily laborers (Table 1). ART was started at a median of 3.3 years (IQR, 1.1–6.4 years) before enrollment. The median baseline CD4 count was 82 cells/µL (IQR, 67–192 cells/µL) and <200 cells/µL for 8 participants. All but 1 had a history of VL, with a median of 2.5 (IQR, 1–8) prior episodes.
Table 1.
Sociodemographics and History of Visceral Leishmaniasis and Human Immunodeficiency Virus (HIV) of People With HIV Included in the Case Series, Northwest Ethiopia, 2017–2021
| Case | Age, y | Sex | Residence in Study Area (VL-Endemic) | Occupation | Years of HIV | Years of ART | No. of Previous VL Episodes | No. of VL Episodes in the Study | CD4 Count, Cells/µL |
|---|---|---|---|---|---|---|---|---|---|
| Chronic VL/HIV cases | |||||||||
| 1 | 20 | Male | Permanent, nonnative | Daily laborer | 5.4 | 5.1 | 6 | 6 | 90 |
| 2 | 28 | Male | Temporary | Daily laborer | 3.6 | 3.6 | 8 | 5 | 32 |
| 3 | 30 | Male | Permanent, nonnative | Daily laborer | 6.5 | 6.4 | 3 | 4 | 50 |
| 4 | 31 | Male | Permanent, nonnative | Daily laborer | 1.3 | 1.1 | 0 | 4 | 68 |
| 5 | 42 | Male | Temporary | Daily laborer | 3.9 | 2.8 | 9 | 5 | 302 |
| 6 | 31 | Male | Permanent, native | Daily laborer | 3.1 | 3.1 | 1 | 4 | 67 |
| 7 | 45 | Male | Permanent, native | Daily laborer | 13.0 | 12.4 | 11 | 3 | 192 |
| 8 | 28 | Male | Permanent, native | Daily laborer | 1 | 1 | 2 | 4 | 458 |
| 9 | 37 | Male | Temporary | Farmer | 0.1 | 0.1 | 1 | 3 | 79 |
| 10 | 25 | Male | Permanent, nonnative | Daily laborer | 7.0 | 7.0 | 1 | 3 | 85 |
| PWH with chronic ALI (PCR and KAtex positive) | |||||||||
| 1 | 27 | Male | Permanent, native | Daily laborer | 0.6 | 0.6 | 0 | 0 | 350 |
| 2 | 37 | Male | Permanent, nonnative | Daily laborer | 0.2 | 0.2 | 0 | 0 | 78 |
| 3 | 60 | Male | Permanently, native | Farmer | 1.4 | 0.1 | 0 | 0 | 135 |
Abbreviations: ALI, asymptomatic Leishmania infection; ART, antiretroviral treatment; KAtex, Leishmania urine antigen test; PCR, polymerase chain reaction; PWH, people with human immunodeficiency virus; VL, visceral leishmaniasis.
For the 10 chronic VL cases, follow-up ranged between 12 and 37 months (median, 28 [IQR, 19–32 months]). Over this time, they had a median of 4 (IQR, 3–4; range, 3–6) VL treatment episodes, summing to a total number of experienced VL treatments (combined before and during the study) of 4 to 14 (median, 6.5 [IQR, 4–12]). For instance, case 5 had 9 episodes prior to enrollment and experienced the 10th–14th VL treatment episode during the study, whereas case 9 had 11 previous episodes and had the 12th–14th VL treatment during follow-up.
Additionally, we included 3 PWH with persistently positive results on Leishmania blood PCR and urine antigen test, but without a VL history and without developing disease (VL) during the 9–24 months of follow-up. They were all male, with the age ranging between 27 and 60 years. All 3 were stable residents, including 2 born in the study area. ART had been started within a year prior to enrollment, with baseline CD4 counts ranging from 78 to 350 cells/µL.
Leishmania Markers Over Time
An overview of the pattern of Leishmania markers over time is given in Table 2 for the 5 most illustrative cases (having visits during as well as in between VL treatment episodes) and in Supplementary Table 1 for the other 5. Overall, Leishmania PCR blood levels were strongly positive for most of the follow-up time (Table 2), with a median Ct value of 26.0 (IQR, 23.1–30.5). This included the period before VL onset and during and between the repeated VL treatment episodes. While all displayed an increase in the Ct levels (corresponding with lower parasite levels) of the Leishmania PCR by the end of treatment of the first VL episode, only 4 had an undetectable Leishmania PCR at the end of treatment. Similarly, the urine antigen tests were strongly positive on all but a few time points, with no to minimal decreases during treatment. In general, CD4 counts were low throughout follow-up. Three participants died (cases 1, 5, and 7). For several participants (eg, case 2, 3, and 5), aiming for parasitological cure was abandoned at some point in time. Case 2 (month 18 visit), case 3 (month 28 visit), and case 5 (month M31 visit) were discharged after clinical improvement despite failing to achieve a negative test of cure; for case 2, treatment was not initiated at the subsequent visit with VL suspicion (month 27) despite a 1+ positive diagnostic tissue aspirate, as parasitological cure was not achieved at the previous visit, the general condition was fair, and starting VL treatment was not deemed to have clear clinical benefit.
Table 2.
Overview of Leishmania Markers in 5 People With Human Immunodeficiency Virus With Chronic Visceral Leishmaniasis, Northwest Ethiopia, 2017–2021
| Marker | Study Time Point | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1a | M0 | M3 | M5/Tx | EOT | M9 | M11 | M14 | M17 | M22 | M28 | M35 |
| rK39 RDT | + | + | + | + | + | + | + | + | + | + | + |
| rK39 ELISA | + | + | + | + | + | + | + | + | + | + | + |
| DAT | + | + | + | + | + | + | + | + | + | + | + |
| KAtex | 3 | 2 | 3 | 3 | 0 | 2 | 3 | 3 | … | 2 | 3 |
| PCR Ct | 40.9 | 36.4 | 27.3 | – | 36.9 | 32.9 | 25.6 | 27.9 | … | 27.5 | 25.6 |
| BMA | … | … | … | … | … | … | … | … | 1 | … | … |
| SA | 0 | … | 4 | 0 | 0 | 0 | 5 | 4 | … | 6 | 6 |
| CD4 | 90 | … | 50 | … | 63 | … | 99 | … | … | 98 | … |
| Case 2a | M0 | M3 | M4/Tx | EOT | M7 | M9 | M12 | M18 | M27 | M32 | … |
| rK39 RDT | – | – | – | – | – | – | – | – | – | … | … |
| rK39 ELISA | – | – | – | – | – | – | – | – | – | … | … |
| DAT | + | + | + | + | + | + | + | + | + | … | … |
| KAtex | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 2 | … | … |
| PCR Ct | 37.5 | 31.6 | 27.2 | – | 23.4 | 31.2 | 24.7 | 26.9 | 21.3 | … | … |
| BMA | 0 | … | 3 | 0 | 1 | … | 0 | … | 1 | … | … |
| SA | … | … | … | … | … | … | … | 6 | … | 6 | … |
| CD4 | 32 | … | 19 | … | 12 | 25 | … | 7 | 87 | … | … |
| Case 3 | M0 | M3 | M6/Tx | EOT | M10 | M15 | M18 | M21 | M28 | … | … |
| rK39 RDT | + | + | + | + | + | + | + | + | + | … | … |
| rK39 ELISA | + | + | + | + | + | + | + | + | + | … | … |
| DAT | + | + | + | + | + | + | + | + | + | … | … |
| KAtex | 0 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | … | … |
| PCR Ct | 22.5 | 29 | 19.8 | – | 23.4 | 21.8 | 21.6 | 22 | 19.8 | … | … |
| BMA | … | … | 5 | 1 | … | 4 | … | 4 | 5 | … | … |
| SA | … | … | … | … | … | … | … | … | … | … | … |
| CD4 | 50 | … | 59 | … | 102 | 48 | 55 | 45 | … | … | … |
| Case 4 | M0 | M3 | M9/Tx | EOT | M13 | M18 | M19 | M25 | M28 | M29 | … |
| rK39 RDT | – | – | + | + | – | + | + | + | + | – | … |
| rK39 ELISA | – | – | + | + | – | + | + | – | – | – | … |
| DAT | – | – | – | – | – | – | ? | + | + | + | … |
| KAtex | 0 | 0 | 3 | 1 | 0 | 3 | 3 | 3 | 2 | 2 | … |
| PCR Ct | – | – | 25 | – | 41 | 24 | 23 | 24 | 29 | 24 | … |
| BMA | … | … | … | 0 | … | … | 4 | 2 | 0 | 1 | … |
| SA | … | … | 5 | … | … | … | … | … | … | … | … |
| CD4 | 68 | 367 | … | … | 116 | 10 | 25 | … | … | 7 | … |
| Case 5a | M0 | M2 | M3/Tx | EOT | M8 | M14 | M15 | M31 | M37 | … | … |
| rK39 RDT | + | + | + | + | + | + | + | + | … | … | … |
| rK39 ELISA | + | + | + | + | + | + | + | + | … | … | … |
| DAT | + | + | + | + | + | + | + | + | … | … | … |
| KAtex | 0 | 1 | 3 | 3 | 3 | 3 | 2 | 3 | … | … | … |
| PCR Ct | 29 | 26.4 | 25.6 | 28.3 | 0 | 27 | 25.6 | 22.7 | … | … | … |
| BMA | … | … | … | 0 | … | … | 5 | 5 | … | … | … |
| SA | 0 | … | 6 | … | 6 | … | … | … | 4 | … | … |
| CD4 | 302 | … | 95 | … | 146 | 167 | … | … | … | … | … |
Bolded values indicate time points with visceral leishmaniasis treatment; non-bold values indicate time points without VL treatment. Study-related Leishmania tests such as rK39 ELISA, DAT, Leishmania PCR, and urine antigen were not available to the physician at the time of the clinical visit. CD4 values are cells/μL; values for BMA & SA are parasite grade (0 if negative; 1+ to 6+); KAtex results are reported as 0 (negative), 1+, 2+ or 3+.
Abbreviations: –, negative; +, positive; BMA, bone marrow aspirate; Ct, cycle threshold value; DAT, direct agglutination test; ELISA, enzyme-linked immunosorbent assay; EOT, end of treatment; KAtex, Leishmania urine antigen test; M, month; PCR, polymerase chain reaction; RDT, rapid diagnostic test; SA, spleen aspirate; Tx, start of visceral leishmaniasis treatment; CD4 values are cells/µL.
aIndividuals enrolled in the study after a negative test of cure.
Table 3 displays the Leishmania markers of the 3 cases with persistent ALI. While they had no VL history and VL was never diagnosed during follow-up, Leishmania PCR on blood and urine antigen tests were consistently and generally strongly positive during follow-up, over a period of 9–24 months. The median PCR Ct value was 24.7 (IQR, 23.0–29.5). ALI case 1 underwent bone marrow aspiration at month 24, with negative results. CD4 counts were consistently <200 cells/µL for 2 cases but not for ALI case 3. While platelets remained normal throughout follow-up, the levels of hemoglobin and white blood cells tended to be decreased, but only slightly and remained fairly stable throughout.
Table 3.
Overview of Leishmania Markers in 3 People With Human Immunodeficiency Virus With Chronic Asymptomatic Leishmania Infection but Persistently Positive Leishmania Markers in Blood Polymerase Chain Reaction and Urine Antigen, Northwest Ethiopia, 2017–2021
| Marker | Study Time Point | ||||||
|---|---|---|---|---|---|---|---|
| ALI case 1 | Month 0 | Month 3 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 |
| rK39 RDT | + | + | + | … | + | … | + |
| rK39 ELISA | 449 | 186 | 46 | … | 31 | … | 136 |
| DAT | 1/1600 | 1/3200 | 1/25 600 | … | 1/204 800 | … | 1/204 800 |
| PCR Ct | 38.6 | 39.5 | 32.3 | - | 29.5 | … | 24.9 |
| KAtex | 0 | 2 | 2 | 0 | 3 | 1 | 3 |
| BMA | … | … | … | … | … | … | 0 |
| CD4 | 135 | … | 67 | … | 48 | … | 36 |
| Hb | 12.7 | 13 | 10.3 | 10.2 | 9.9 | … | 11.2 |
| WBC | 3.97 | 4.04 | 2.08 | 3.13 | 3 | … | 3.4 |
| Platelets | 273 | 285 | 220 | 274 | 271 | … | 263 |
| ALI case 2 | Month 0 | Month 3 | Month 6 | Month 9 | Month 12 | … | … |
| rK39 RDT | + | + | + | + | + | … | … |
| rK39 ELISA | >800 | >800 | >800 | >800 | >800 | … | … |
| DAT | 1/204 800 | 1/204 800 | 1/204 800 | 1/204 800 | 1/204 800 | … | … |
| PCR Ct | 23.4 | 26.4 | 24.4 | 22.8 | 23 | … | … |
| KAtex | 2 | 2 | 3 | 3 | 3 | … | … |
| CD4 | 78 | … | 144 | … | 82 | … | … |
| Hb | 10.7 | 11.3 | 11.3 | 12 | 9.8 | … | … |
| WBC | 3.01 | 3.35 | 6.16 | 4.45 | 3.1 | … | … |
| Platelets | 226 | 251 | 249 | 228 | 212 | … | … |
| ALI case 3 | Month 0 | Month 3 | Month 6 | Month 9 | … | … | … |
| rK39 RDT | – | – | – | – | … | … | … |
| rK39 ELISA | – | – | – | – | … | … | … |
| DAT | 1/204 800 | 1/25 600 | 1/51 200 | 1/204 800 | … | … | … |
| PCR Ct | 25.9 | 24.0 | 22.0 | 21.3 | … | … | … |
| KAtex | 2 | 2 | 3 | 0 | … | … | … |
| CD4 | 350 | … | 399 | … | … | … | … |
| Hb | 11 | 10.2 | 11 | 8.2 | … | … | … |
| WBC | 2.13 | 2.5 | 4.98 | 2.8 | … | … | … |
| Platelets | 173 | 187 | 208 | 161 | … | … | … |
Study-related Leishmania tests such as rK39 ELISA, DAT, Leishmania PCR, and urine antigen were not available to the physician at the time of the clinical visit. CD4 values are cells/µL; values for BMA & SA are parasite grade (0 if negative, 1+ to 6+); KAtex results are reported as 0 (negative), 1+, 2+ or 3+; platelet values represent platelet count/µL.
Abbreviations: –, negative; +, positive; ALI, asymptomatic Leishmania infection; BMA, bone marrow aspirate; Ct, cycle threshold value; DAT, direct agglutination test, expressed in titer (positive if titer ≥1/1600); ELISA, enzyme-linked immunosorbent assay, expressed in units/mL (positive if >15 U/mL); Hb, hemoglobin (gram/deciliter); KAtex, Leishmania urine antigen test; PCR, polymerase chain reaction; RDT, rapid diagnostic test; WBC, white blood cell count (cells/µL).
DISCUSSION
To our knowledge, this is the first description of PWH from an L. donovani–endemic area with chronic high-level parasitemia. Markers were positive during but also between the repeated VL treatment episodes. In addition, we describe 3 PWH without VL before or during the study who displayed high levels of Leishmania parasitemia and antigenuria for 9–24 months, without developing VL. To the best of our knowledge, these are the first 3 such cases from both L. infantum– and L. donovani–endemic areas.
While the chronic VL cases described fit the entity of active chronic VL described in France [11], we did not perform culture and thus could not demonstrate that viable parasites could be recovered from the blood. Nevertheless, the persistent and high direct parasite markers in blood and urine indicate active replication since Leishmania DNA detected by PCR in the blood is degraded rapidly [20].
Xenodiagnosis studies performed in L. infantum–endemic areas in VL cases with HIV or other immunosuppressive conditions found they were more infectious to sandflies than immunocompetent individuals and also demonstrated that PWH with ALI were capable of transmitting the parasite [21, 22]. Xenodiagnosis studies in PWH in L. donovani–endemic areas—where transmission is anthroponotic—remain to be conducted, including PWH with symptomatic and asymptomatic Leishmania infection.
A characteristic feature of superspreaders is that, even when relatively rare, they contribute to a relatively large part of transmission [5, 6]. For example, a small number of highly infectious dogs have been shown to harbor close to 90% of Leishmania parasites [23]. In Ethiopia, a modeling study suggested that 3.2% of humans could contribute to 53%–79% of the infected sandfly population [24]. In northwest Ethiopia, the HIV prevalence in VL cases remains at around 20% [9, 25]. Among the 34 incident VL cases in the PreLeisH study, 10 (29%) developed at least 3 VL episodes over the 12–37 months of follow-up. Chronic VL cases could potentially be infectious for very prolonged periods, and given the repeated exposure to VL treatment, potentially also of drug-resistant parasites. These individuals are also highly mobile. This case series only included chronic VL cases (≥3 VL episodes in the study). However, several of the 9 patients—not included in this study—with 2 VL episodes during follow-up also had persistent parasitemia, so this condition could be more common.
PWH with ALI and chronically high parasitemia were rather rare. Only 3 were identified with consistent parasitemia among the 412 individuals in the PreLeisH study without VL treatment episodes and with at least 3 PCR measurements done during follow-up (ie, 0.7% of study participants). Even while few, they could constitute hidden reservoirs of VL transmission for a long time, as such individuals would not seek VL care. Further studies on the role of superspreaders are required to inform the East African VL elimination initiative [4].
While qPCR levels in peripheral blood generally correlated with infectiousness in studies from L. infantum–endemic areas [21, 22], recent studies have suggested that the skin is a much underappreciated site of active parasite replication [5, 23, 26]. In (symptomatic) dogs, skin qPCR parasite loads were higher, even at levels similar to the spleen [23, 27], and correlated well with infectivity during xenodiagnosis [23, 27]. To assess this in humans, it could be useful to conduct studies using skin microbiopsy devices [28], which mimic the sandfly bite, in parallel with qPCR on peripheral blood and ideally xenodiagnosis. Reliable tools for infectivity would also be needed to assess whether reducing parasite load with treatment/prophylaxis has an impact on the transmission potential. While qPCR testing is currently not available at most health facilities in East African countries, highly accurate and simple loop-mediated isothermal amplification assay has been proposed as a molecular point-of-care test adapted to resource-constrained settings [29].
Strengths of our study include that it was conducted within a well-established clinical research network, with due attention to high-standard laboratory procedures and quality control, and oversight by a Clinical Trials Unit. There are a number of important limitations to acknowledge. As mentioned, xenodiagnosis studies would have strengthened the public health relevance of our findings. More frequent visits between treatment episodes would have allowed more refined analysis of the evolution of Leishmania parasitemia. For the 3 individuals with ALI but high parasitemia, it remains unsure whether they developed VL after the study.
CONCLUSIONS
We describe 10 cases of active chronic VL in PWH, displaying multiple VL episodes over a 37-month follow-up period. Both during and in between VL treatment, Leishmania PCR and urine antigen tests were consistently and generally strongly positive, indicating prolonged opportunities for transmission. We also report 3 cases without VL history but with persistently strongly positive Leishmania markers, which could act as hidden sources of infection. Both groups could act as superspreaders and constitute a major challenge for VL elimination in the area. If the infectiousness of these individuals is confirmed in future xenodiagnosis studies, simple biomarkers of infectiousness should be developed to identify the most infectious individuals, complemented by studies on interventions to reduce transmission from these individuals.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Supplementary Material
Contributor Information
Johan van Griensven, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Saskia van Henten, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Aderajew Kibret, Public Health Department, Médecins sans Frontières, Amsterdam, The Netherlands.
Mekibib Kassa, Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia.
Hailemariam Beyene, Public Health Department, Médecins sans Frontières, Amsterdam, The Netherlands.
Saïd Abdellati, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Annelies de Hondt, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Wim Adriaensen, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Florian Vogt, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; The Kirby Institute, University of New South Wales, Sydney, Australia; National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia.
Myrthe Pareyn, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Koert Ritmeijer, Public Health Department, Médecins sans Frontières, Amsterdam, The Netherlands.
Ermias Diro, Department of Internal Medicine, University of Gondar, Gondar, Ethiopia; Department of Internal Medicine, University of Washington, Seattle, USA.
Notes
Acknowledgments. The authors thank all of the study participants and the staff involved in the study at the Abdurafi health center and the Gondar Leishmaniasis Research and Treatment Center.
Financial support. The PreLeisH study was funded by the Institute of Tropical Medicine (Antwerp, Belgium) , grant no. 757013.
References
- 1. van Griensven J, Diro E. Visceral leishmaniasis: recent advances in diagnostics and treatment regimens. Infect Dis Clin North Am 2019; 33:79–99. [DOI] [PubMed] [Google Scholar]
- 2. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018; 392:951–70. [DOI] [PubMed] [Google Scholar]
- 3. World Health Organization Leishmaniasis. Key facts. 2022. Available at: https://www.who.int/health-topics/leishmaniasis. Accessed 1 December 2023.
- 4. Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as a public health problem in East Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob Health 2021; 9:e1763–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Courtenay O, Peters NC, Rogers ME, Bern C. Combining epidemiology with basic biology of sand flies, parasites, and hosts to inform leishmaniasis transmission dynamics and control. PLoS Pathog 2017; 13:e1006571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Woolhouse M. Quantifying transmission. Microbiol Spectr 2017; 5. doi: 10.1128/microbiolspec.MTBP-0005-2016 [DOI] [PubMed] [Google Scholar]
- 7. Cloots K, Marino P, Burza S, et al. Visceral leishmaniasis–HIV coinfection as a predictor of increased Leishmania transmission at the village level in Bihar, India. Front Cell Infect Microbiol 2021; 11:604117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Diro E, Lynen L, Ritmeijer K, et al. Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis 2014; 8:e2869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Mohammed R, Fikre H, Schuster A, et al. Multiple relapses of visceral leishmaniasis in HIV co-infected patients: a case series from Ethiopia. Curr Ther Res Clin Exp 2020; 92:100583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Bourgeois N, Bastien P, Reynes J, et al. ‘Active chronic visceral leishmaniasis’ in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 2010; 11:670–3. [DOI] [PubMed] [Google Scholar]
- 12. ClinicalTrials.gov . Predicting Visceral Leishmaniasis in HIV Infected Patients (PreLeisH). Available at: https://clinicaltrials.gov/ct2/show/NCT03013673. Accessed 1 December 2023.
- 13. Ethiopian Ministry of Health . Guideline for diagnosis, treatment and prevention of leishmaniasis in Ethiopia. 2nd ed. 2013. Available at: https://www.afrikadia.org/wp-content/uploads/2018/08/VL_Guidelines_Ethiopia_2013.pdf. Accessed 1 December 2023. [Google Scholar]
- 14. World Health Organization (WHO) . Control of the leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO technical report series 9492010. Geneva, Switzerland: WHO, 2010.
- 15. World Health Organization . WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. 2022. Available at: https://www.who.int/publications/i/item/9789240048294. Accessed 1 December 2023 [PubMed]
- 16. van Griensven J, van Henten S, Mengesha B, et al. Longitudinal evaluation of asymptomatic Leishmania infection in HIV-infected individuals in north-west Ethiopia: a pilot study. PLoS Negl Trop Dis 2019; 13:e0007765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Melkamu R, Berhane N, Jacobs BKM, et al. PCR for detection of Leishmania donovani from microscopically negative tissue smears of suspected patients in Gondar, Ethiopia. PLoS Negl Trop Dis 2023; 17:e0011128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Mohammed R, Melkamu R, Pareyn M, et al. Detection of asymptomatic Leishmania infection in blood donors at two blood banks in Ethiopia. PLoS Negl Trop Dis 2023; 17:e0011142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Ibarra-Meneses AV, Corbeil A, Wagner V, Onwuchekwa C, Fernandez-Prada C. Identification of asymptomatic Leishmania infections: a scoping review. Parasit Vectors 2022; 15:5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Prina E, Roux E, Mattei D, Milon G. Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR. Microbes Infect 2007; 9:1307–15. [DOI] [PubMed] [Google Scholar]
- 21. Molina R, Jimenez M, Garcia-Martinez J, et al. Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context. PLoS Negl Trop Dis 2020; 14:e0008253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Ferreira GR, Castelo Branco Ribeiro JC, Meneses Filho A, et al. Human competence to transmit Leishmania infantum to Lutzomyia longipalpis and the influence of human immunodeficiency virus infection. Am J Trop Med Hyg 2018; 98:126–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Courtenay O, Carson C, Calvo-Bado L, Garcez LM, Quinnell RJ. Heterogeneities in Leishmania infantum infection: using skin parasite burdens to identify highly infectious dogs. PLoS Negl Trop Dis 2014; 8:e2583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Miller E, Warburg A, Novikov I, et al. Quantifying the contribution of hosts with different parasite concentrations to the transmission of visceral leishmaniasis in Ethiopia. PLoS Negl Trop Dis 2014; 8:e3288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Akuffo H, Costa C, van Griensven J, et al. New insights into leishmaniasis in the immunosuppressed. PLoS Negl Trop Dis 2018; 12:e0006375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Doehl JSP, Bright Z, Dey S, et al. Skin parasite landscape determines host infectiousness in visceral leishmaniasis. Nat Commun 2017; 8:57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Scorza BM, Mahachi KG, Cox AC, et al. Leishmania infantum xenodiagnosis from vertically infected dogs reveals significant skin tropism. PLoS Negl Trop Dis 2021; 15:e0009366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Kirstein OD, Abbasi I, Horwitz BZ, et al. Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of Leishmania donovani. Int J Parasitol 2017; 47:609–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Mukhtar M, Ali SS, Boshara SA, et al. Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). PLoS Negl Trop Dis 2018; 12:e0006264. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.